high purity Doxazosin Mesylate for sale /production CAS NO.77883-43-3

high purity doxazosin mesylate for sale /production

product description

name: methanone,[4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](2,3-dihydro-1,4-benzodioxin-2-yl)-,methanesulfonate (1:1)

cas no.: 77883-43-3

formula: c24h29n5o8s

molecular weight: 547.58

synonyms:

normothen;supressin;uk 33274-27;doxazolazine mesylate;piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-,monomethanesulfonate (9ci);alfadil;cardenalin;cardran;1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfonate;cardura (pharmaceutical);diblocin;[4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](2,3-dihydro-1,4-benzodioxin-2-yl)methanone methanesulfonate (1:1);doxazosin monomethanesulfonate;

melting point: 275-277 °c

boiling point: 718 °c at 760 mmhg

flash point: 388 °c

appearance:white crystalline powder

doxazosin mesylate is an α-blocker drug related to prazosin, specifically acting as an ar (α-1-adrenoceptor) antagonist. doxazosin mesylate inhibits the binding of norepinephrine to the α-1 receptors on the membrane of vascular smooth muscle cells. the primary effect of this inhibition is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular resistance, leading to decreased blood pressure.

company information

hefei lifeon pharmaceutical co., ltdwas founded in 2002.

as a key high-tech enterprise of the national torch plan program， lifeon has a provincial technical center. it shares 16 gmp production lines including tablets, granules, capsules, ointments, gels, apis, oral solutions, and extractions of traditional chinese medicines, and 109 drug approvals. the main products produced and sold include felodipine sustained-release tablets (ii), metformin and glipizide tablets, doxazosin mesylate sustained-release tablets, leuconazole oral liquid, yiqi hewei capsule, kunning capsule, compound earthen skin gel, paeonol ointment and so on, covering cardiovascular, diabetes, digestive, urinary, gynecological, tumor, skin external medicine and other clinical fields.

the company has initiated the talent strategy of "introduction, cultivation and cooperation". according to company development strategy, it is needed to introduce high-end technical personnel at home and abroad as research and development of disciplinary leaders.talents have been introduced including new drug delivery technologies, bio-antibody engineering, chemical synthesis, and impurity analysis and control.